-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 24, BeiGene announced that the European Commission had approved Baiyueze® (Zebutinib) for the treatment of adult patients with Waldenstrom's macroglobulinemia (WM) who had received at least one treatment in the past, or as unsuitable Chemotherapy and immunotherapy are the first-line treatment options for WM patients
Following the positive opinion of the European Medicines Agency (EMA) Committee on Medicines for Human Use (CHMP) in September, Beacon® was approved by the European Commission this time based on the results of the ASPEN trial
Waldenstrom's macroglobulinemia (WM) is a relatively indolent and rare B-cell malignancy, manifested by lymphoplasmic cells secreting monoclonal immunoglobulin M (IgM) invading the bone marrow